ASCO 2024: Osimertinib for unresectable late-stage, EGFR-mutant NSCLC

Among patients with unresectable stage III EGFR-mutated NSCLC, osimertinib led to significantly longer progression-free survival (PFS) than placebo.

In the phase 3 LAURA trial, investigators randomly assigned patients with unresectable EGFR-mutated stage III NSCLC without progression during or after chemoradiotherapy to receive osimertinib or placebo until disease progression occurred or regimen was discontinued.

A total of 216 patients who’d undergone chemoradiotherapy were randomly assigned to receive osimertinib (n = 143) or placebo (n = 73). A significant PFS benefit was seen with omisertinib compared with placebo: median PFS was 39.1 months with osimertinib vs. 5.6 months with placebo (hazard ratio [HR] for disease progression or death, 0.16; 95% confidence interval [CI], 0.10-0.24; P<0.001). Percentage of patients who were alive and progression free at 12 months was 74% with osimertinib and 22% with placebo. Interim overall survival (OS) data (maturity, 20%) showed 36-month OS among 84% of osimertinib recipients vs. 74% with placebo (HR for death, 0.81; 95% CI, 0.42-1.56; P = 0.53). Incidence of grade 3+ adverse events was 35% in the osimertinib group vs. 12% in the placebo group, with radiation pneumonitis (mostly grade 1 to 2) reported in 48% and 38%, respectively. No new safety signals were reported.

Source:

Lu S, et al. (2024, June 2). N Engl J Med. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. https://pubmed.ncbi.nlm.nih.gov/38828946/